An interesting piece about Axiom Bio's work combining cell painting and machine learning to predict toxicity
Alex Kesin@alexkesin
For a decade, techbio optimized the drug discovery "paper mill": more molecules, faster. But the hard part - knowing which ones will work safely in humans - hardly moved at all. Late last year, I spent time with Axiom Bio, a company built around the idea that the real bottleneck is predicting clinical activity in molecules, *not* merely discovering them.
English
